



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/679347/2011

European Medicines Agency decision P/221/2011

of 26 September 2011

on the granting of a product specific waiver for dapagliflozin / metformin hydrochloride (EMEA-001151-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/221/2011

of 26 September 2011

on the granting of a product specific waiver for dapagliflozin / metformin hydrochloride (EMEA-001151-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Bristol-Myers Squibb / AstraZeneca EEIG on 10 May 2011 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 August 2011 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A waiver for dapagliflozin / metformin hydrochloride, film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Bristol-Myers Squibb / AstraZeneca EEIG, Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, UB8 1DH Uxbridge, United Kingdom.

Done at London, 26 September 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)

EMA/PDCO/537168/2011

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMEA-001151-PIP01-11

Scope of the application

Active substance(s):

Dapagliflozin / metformin hydrochloride

Condition(s):

Treatment of diabetes type 2

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Bristol-Myers Squibb / AstraZeneca EEIG

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb / AstraZeneca EEIG submitted to the European Medicines Agency on 10 May 2011 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 15 June 2011.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population and Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 12 August 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition: Treatment of diabetes type 2

The waiver applies to:

- All subsets of the paediatric population from birth to less than 10 years of age;
- for film-coated tablets, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

And to:

- All subsets of the paediatric population from 10 to less than 18 years of age;
- for film-coated tablets, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.